{"name":"DEKK-TEC, Inc.","slug":"dekk-tec-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DM-CHOC-PEN","genericName":"DM-CHOC-PEN","slug":"dm-choc-pen","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"4-Demethyl-4-cholestryloxycarbonylpenclomedine","genericName":"4-Demethyl-4-cholestryloxycarbonylpenclomedine","slug":"4-demethyl-4-cholestryloxycarbonylpenclomedine","indication":"Metastatic breast cancer","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"A-007","genericName":"A-007","slug":"a-007","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"DM-CHOC-PEN","genericName":"DM-CHOC-PEN","slug":"dm-choc-pen","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"4-Demethyl-4-cholestryloxycarbonylpenclomedine","genericName":"4-Demethyl-4-cholestryloxycarbonylpenclomedine","slug":"4-demethyl-4-cholestryloxycarbonylpenclomedine","phase":"phase_2","mechanism":"4-Demethyl-4-cholestryloxycarbonylpenclomedine is a chemotherapy medication that works by inhibiting the enzyme topoisomerase II.","indications":["Metastatic breast cancer","Metastatic ovarian cancer"],"catalyst":""},{"name":"A-007","genericName":"A-007","slug":"a-007","phase":"phase_2","mechanism":"A-007 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}